Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Xynomic Forms Partnership with UCSF for Cancer Drug Trial

publication date: May 23, 2017
Xynomic Pharma, a US-China oncology startup, entered a strategic partnership with the University of California San Francisco to conduct a Phase II/III clinical trial of its lead drug, abexinostat. Abexinostat is an HDAC inhibitor that is designed to overcome chemotherapy resistance, and Xynomic expects it will prove to be best-in-class. The company in-licensed global rights to abexinostat from AbbVie three months ago. Headquartered in Cheyenne, Wyoming, Xynomic also has operations in China. More details....

Stock Symbol: (NYSE: ABBV)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here